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The Impact of COVID-19 on Stock Returns of the Indian Healthcare and 
Pharmaceutical Sector 
Abstract 
Increasing COVID-19 cases has not only impacted health and day-to-day lives of people, but it has also 
had a material effect on India’s economic growth. Stock returns of various sectors are evidence of a 
country’s stagnated growth but the healthcare and pharmaceutical sector might be affected in a different 
manner. The purpose of this paper is to find out how has this pandemic has impacted the healthcare and 
pharma stocks. Daily closing prices of sector specific indexes for 233 days ranging from 15 May 2019 to 
24 April 2020 have been taken to compare different sectors with our test sector, on the basis of different 
criteria. This study has applied the widely used event study methodology on our test sector; calculated 
abnormal returns, cumulative abnormal returns and also tested their significance. Event study approach 
suggests that there have been significant abnormal returns and cumulative abnormal returns in our test 
sector (healthcare and pharmaceutical sector) over the event window, though while comparing it with 
other sectors through another econometric model, the returns are not statistically significant and do not 
explicitly indicate the same. 
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1.1 Healthcare and Pharmaceutical Industries 
 
The importance of the healthcare and pharmaceutical industry is increasing worldwide with an 
increase in life expectancy from 64.2 years in 1990 to 72.6 years in 2019 (United 
Nations,2019). India is the third largest pharmaceutical industry in the world by volume 
(McKinsey & Co. Report, 2020) and it stands out as an attractive destination for establishing 
generic R&D centres and manufacturing units due to low operating cost and high-quality 
products across the value chain. India accounts for 20 per cent of global exports in generics by 
volume2 making it the largest provider of generic medicines globally. India exports to more 
than 200 countries and it accounts for trade worth USD 19.14 billion in FY19 and is expected 
to reach USD 22 billion in FY203. Healthcare has become India’s major sector in terms of both 
revenue and employment. It is estimated to reach USD 372 billion by the end of FY22 with 
rising income, greater health awareness, increased precedence of lifestyle diseases and 
improved access to insurance4. According to World Bank Economic Survey FY18, the 
government’s expenditure on healthcare sector has risen to 1.4 per cent in FY18 from 1.2 per 
cent in FY14. The main aim of the government of India in investing and uplifting these sectors 
is to improve the quality of life of the citizens and prevent them from any future global 
pandemics. And in this twenty-first century, when people travel a lot either because of their 
work or for vacation, it takes a miniscule amount of time for disease to travel along to other 
parts of the world. The impact of infectious diseases is limited not only to humans but also to 





1.2.1 Emergence of the Disease 
 
In recent times, a new pandemic has arisen, named SARS-CoV-2 (severe acute respiratory 
syndrome coronavirus 2) or COVID-19, and its first case is reported to have originated in 
Wuhan, the capital city of Hubei province, China. According to the World Health Organization 
(WHO), the first confirmed case of COVID-19 was found on 8 December 2019. But according 
to Chinese government data (the South China Morning Post), the first confirmed case of 
suffering can be traced back to 17 November 2019. Similar kind of infectious diseases have 
swept the world in the past and it is happening again due to SARS-CoV-2. It has reached 213 
countries and the confirmed cases have skyrocketed to more than 21 lakhs till date5 (WHO). 
Although the virus reached India later than in many other countries according to the statement 
made by the Ministry of Health and Family Welfare, the first case in India was reported on 30 
January of a student studying in Wuhan, China, who was visiting Kerala. Whereas WHO 
declared COVID-19 as a global pandemic on 11 March, India reported its first fatality due to 
the virus on 12 March, in Karnataka6.Seeing the impact of the virus and increasing positive 
                                                                
2 See Press release – Press Information Bureau, December 2018 
3 See IBEF 2019 report on  PHARMACEUTICALS ( https://www.ibef.org/download/Pharmaceuticals-October-
2019.pdf) 
4 See IBEF 2020 report on Healthcare sector (https://www.ibef.org/industry/healthcare-presentation) 
5 Data till 18th March 2020 
6 Press release by Government of India on 12 March. 
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cases on a daily basis at a rapid pace, India was brought to the state of 21-day complete 
lockdown from 24 March,7 to prevent its citizens from the virus and curb the epidemic. 
Lockdown was implemented by constraining people to their houses under quarantine and 
shutting down all transport facilities, manufacturing of non-essential products, hospitality 
services, educational institutions and places of worship8. Lockdown was supposed to end on 
15 April, but looking at the conditions of the country within the 21-day period, as confirmed 
cases and deaths were increasing, lockdown was extended for further 19 days till 3 May 20209. 
According to the Indian Council of Medical Research report published on 17 April 2020, a total 
of 3,18,449 individuals had been tested for the virus and 14,098 been confirmed positive. The 
graph on the next page is updated for figures until 17 March end of the day, where total positive 
cases are implied on the secondary y-axis. According to the COV-IND-19 study group, a range 
of 4,836–28,925 confirmed cases by 15 April and 58,643–9,15,000 cases by 15 May are 
estimated10. India had already crossed the prediction on the lower end of the range but was less 
than half of the upper end on 15 April, which implies that India could have been worse off if 
preventive measures were not taken. 
 
2.2 Impact of COVID-19 on Economy 
 
With the whole economy having been shut down except the essential services, many sectors 
are bound to record low production volume and revenue for the final quarter of FY20 as well 
as for next year. Some industries that have an inhibit condition of mass gatherings will be worst 
hit, like entertainment, sports, aviation, transportation, restaurants and hospitality industry. For 
instance, the Chinese hotel market witnessed a 71 per cent year-over-year decline of occupancy 
on 23–26 January11. All of this added up to a lower GDP growth for the country – we reported 
a six-year low growth rate of 4.7 per cent in the third quarter12 of the current fiscal year. 
COVID-19 outbreak could cost the economy Rs. 6.3–7.2 lakh crore during the 21-day 
lockdown period13.The GDP growth may slow down to 4 per cent in the financial year ending 
on 31 March 202114. The effect on India’s trade could be around USD 348 million as a 
consequence of the virus outbreak (UNCTAD, 2020). For India, the overall export impact in 
the chemical sector is estimated to be the largest at USD 129 million, followed by textile and 
clothing at USD 64 million, automobile industry at USD 34 million and electricity at USD 12 
million (UNCTAD 2020). 
                                                                
7 Ministry of Home Affairs (MHA order No. 40-3/2020-DM-I(A). 
8 Annexure to MHA order No. 40-3/2020-DM-I(A). 




12 Press Release by NSO, MOSPI dated 28 Feb 2020. 
13 Please see https://www.nationalheraldindia.com/business/economic-cost-of-21-day-lockdown-is-rs-72-lakh-
crore 









Figure 1: Timeline of COVID-19 effect in India 
 
 
Data Source: Ministry of Health & Family Welfare; Indian Council of Medical Research 
Note : Graph is compiled by author 
Figure 2: Number of COVID-19 cases in India 
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Underestimating the results of companies due to reduced operation has led to uncertainty 
among investors about the future of companies, and has made the stock market volatile. Both 
BSE Sensex and NSE Nifty crashed by 23 per cent in the month of March. Sensex saw its 
biggest drop since 2001 when it fell 15 per cent. Nifty50’s previous biggest drop was in March 
1993 where it dropped by 19.6 per cent15. Although these are not the first instances of both 
indices falling more than 20 per cent in a month, it has happened twice before, in 1992 during 
the Harshad Mehta case and in 2008 during the financial crisis. Even though both of the indices 
have seen some upward movement in April 2020, the equity market still remains volatile due 
to the uncertainty in domestic and global markets. 
 
The remainder of this paper has been organised as follows. Section 2 discusses literature review 
and Section 3 illustrates the data sources and methodology. Section 4 discusses the econometric 
framework and the last section concludes the paper. 
 
2. LITERATURE REVIEW 
 
The stock market reflects the current situation of the economy and it reacts to major events. 
Past literature has shown the same from time to time, for example, how news affects the stock 
market (Li, 2018) or how stock market responded to foot-and-mouth disease (FMD) outbreaks 
in Korea (Pendell D. et al., 2013). The Chinese stock market has shown significant negative 
returns related to the daily growth of both total confirmed cases and total cases of deaths caused 
by COVID-19 (Al Awadhi A. M. et al., 2020). 
On similar lines as COVID-19, in 2003 SARS epidemic had spread throughout the world. 
SARS impacted the airline stock of Canada, China, Hong Kong, Singapore and Thailand. A 
study also found that airline stocks were more sensitive to news about SARS relative to the 
average non-aviation sector (Elaine Loh, 2006). The Ebola epidemic in Africa also led to 
disinvestment from equity mutual funds and the disinvestment increased with the coverage of 
media (Alfonso Del Giudice & Andrea Paltrinieri, 2017). SARS hit the tourism industry worst; 
it saw the highest stock decline within a month (approximately 29 per cent). This was supported 
by a study that showed that Taiwanese hotel stocks showed significant cumulative abnormal 
returns on and after the day of outbreak of the epidemic (Chen, Jang & Kim, 2007). The 
outbreak of SARS impacted the hotel stock returns in Taiwan, not only because of loss in 
revenue for the hotels but also due to higher discount rates offered by them (Chen, 2010. Apart 
from the tourism sector, investment, retail sales, restaurants, hotels and the air transport 
industry were among other sectors that were adversely impacted on a great scale (Keogh-
Brown & Richard, 2008). Taiwanese biotechnology stocks showed significantly positive 
cumulative abnormal returns at the time of outbreak of enterovirus 71, dengue fever, SARS 
and H1N1 (Wang et al., 2013). 
 
In times of crisis, medical and healthcare companies are in heavy demand for supplying the 
necessary medicines and equipment; not only that but they also have to spend on R&D to 
develop vaccines for the disease. Since the revenue margin of these companies will increase in 
the upcoming quarters, investors take note of this and their share price may increase due to 
bulk buying. But since Indian companies procure almost 70 per cent of the active 
pharmaceutical ingredients (APIs) for their medicines from China (Bloomberg), and as 
factories are closed in China due to the coronavirus outbreak, Indian pharma industry is already 
                                                                
15 Source: Bloomberg database 
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under pressure (Chatterjee P. 2020). Existing literature indicates that infectious diseases 
negatively affect the stock prices of several sectors, but the question is, do they also impact the 
stocks of healthcare and pharma sector negatively? According to the literature, there existed 
significant positive cumulative abnormal returns before the announcement date of virus and 
significantly negative cumulative abnormal returns after the announcement date (Yang, Wang 
& Chen, 2010). 
The SARS crisis did bring negative impact on tourism, wholesale and retail, but the 
biotechnology sector saw positive shocks from the impact of the crisis (Yang & Chen, 2009). 
There exists hardly any literature which has taken Indian stocks into consideration for such 
major epidemics. The purpose of this paper is to investigate how the outbreak of SARS-CoV-
2 affected stock performance within the healthcare and pharmaceutical industry in comparison 
to the expected return from them, and the overall stock market returns during the event period. 
 
3. DATA AND METHODOLOGY 
 
We have taken daily closing prices of stock indexes of different sectors and the Bombay Stock 
Exchange SENSEX (BSE SENSEX) obtained from E-Research and BSE website. BSE 
SENSEX is a combined weighted stock index of top 30 companies in India, distributed among 
various sectors. For each index we have used closing prices of 233 trading days, starting from 
15 May 2019 till 24 April 2020. 
To get a clear picture of how healthcare sector has performed, we have performed analysis on 
various levels. We started with the simplest form of analysis by using data of different sectors 
and narrowed it down further step by step into performance of healthcare and pharmaceutical 
sector. 
We first calculated the return of different indexes for last month of our study time-period by 
using the closing prices of first day and last day of month (IR= PriceApril/PriceMarch). Results 
from this give us a blurry picture of how different sectors have performed over the last month; 
remember that these returns are of a period after the announcement of pandemic. 
To gain more clarity in the results, we compared mean returns among all sectors for two 
different time periods – pre-event mean return and post-even mean return. The pre-event mean 
return window is of 177 days, starting from 16 May 2019 till 31 January 2020, and post-event 
mean return window is of 55 days from 1 February 2020 to 24 April 2020. To test the 
significance of these returns we also applied t-test for two samples assuming unequal variances. 
 
The last step while comparing different sectors with our test sector (that is, healthcare and 
pharmaceutical sector) was to plot a graph of daily abnormal returns of both sectors over our 
post-event window. This graphical representation would help us to see if there were abnormal 
returns in any other sector too apart from the test sector; and if not, it would strengthen the case 
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Event study is widely used in financial economics to determine whether there has been any 
effect of a particular event or information on the stock performance. To see the impact of 
coronavirus on India’s healthcare and pharmaceutical industry, we will apply event study 
model here. The event day has been taken as the day on which India reported its first fatality 
due to the virus – 12 March 2019. The study period is of 233 days, which is divided into an 
estimated period of 178 trading days and event period of 55 trading days. BSE SENSEX index 
is taken as a benchmark index to calculate abnormal return of all sectors. The expected return 
(𝑅𝑖𝑡) is derived using the market model and Ordinary Least Square (OLS), which is based on 
the following regression model: 
 
 
𝑅𝑖𝑡 = 𝛼𝑖 + 𝛽𝑖𝑅𝑚𝑡 + 𝜀𝑖𝑡 
 
Rit – Expected return of sector 
 
Rmt – Market return return of sensex 
βi – unbiased beta coefficient 
αi – intercept 
 
the abnormal return (AR) is calculated as – 
 
𝐴𝑅𝑡 = 𝑅𝑘𝑡 − 𝑅𝑖𝑡 
 
Rkt – Normal or actual return 
 
Rkt, Rmt = (𝑃𝑟𝑖𝑐𝑒𝑛/𝑃𝑟𝑖𝑐𝑒𝑛−1) ∗ 100 
 
t(𝐴𝑅t )  =   𝐴𝑅𝑡  
             √𝑉𝑎𝑟(𝐴𝑅𝑝𝑟𝑒) 
 
𝐴𝑅𝑝𝑟𝑒 – Abnormal return of pre-event period 
 
4. EMPIRICAL RESULTS 
 
By looking at the last 30 days trading return (one month includes only those days on which the 
market was open, from 9 March 2020 to 24 April 2020) of different indexes, only two sectors 
have provided positive returns. BSE FMCG index has increased by 2.91 per cent and the test 
sector (BSE Healthcare) has given a 14.19 per cent return, much higher than any other sector. 
All other sectors gave negative returns – for example, Consumer Discretionary lost almost 19 
per cent in a month, Banks fell by 26 per cent and Realty sector lost a whopping 30.7 per cent 
in a month. These results give a slight indication that the test sector might have provided 
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Table I - One-month index return 
 
Sector 1-Month % Return 
BSE SENSEX -12.09% 
BSE HEALTHCARE 14.19% 
BSE AUTO -18.34% 
BSE BASIC MATERIALS -17.27% 
BSE CONSUMER DISCRETIONARY -18.09% 
BSE REALTY -30.68% 
BSE IT -10.97% 
BSE BANKEX -26.05% 
BSE FMCG 2.91% 
BSE TECK -9.87% 
BSE METAL -20.12% 
BSE OIL & GAS -4.16% 
BSE INDIA MANUFACTURING INDEX -4.20% 
BSE INDIA INFRASTRUCTURE INDEX -13.74% 
Note: Above table is based on author’s analysis 
 
The results obtained from testing the mean returns and its significance in the pre-event and 
post-event period are given in Table II. Figures under the pre-event mean column are the mean 
of daily returns generated over the period 16 May 2019 to 31 January 2019, while those under 
post-event relate to the period 1 February 2020 to 24 April 2020. T-statistic provides the test 
statistics of testing the mean differences with a two tailed test assuming unequal variances. 
 
Benchmark index SENSEX fell down by a staggering 47.69 per cent in the post-event period, 
similarly other sectoral indices also felt the brunt of the pandemic. A few sectors that were 
impacted the most were realty, banks and financial institutions and metal, whereas the test 
sector BSE Healthcare gave positive returns of 18 per cent in the post-event period. Though 
only BSE Realty index has given significantly different results at 0.05 level and that too 
negative returns, positive return of test sector is an indication that they can be a safe bet for 
investors who want to go long on them. 
 
Since post-mean returns are not significantly different from pre-mean returns for the test 
sector, we need to test further using another method. One such method that is used here is of 
abnormal returns during the post-event period (from 1 February 2020 to 24 April 2020), by 
plotting daily abnormal returns of healthcare index with every other sectoral index on a graph 
and comparing them. Post-event period can be divided into two parts; one from 1 February 
2020 to 11 March 2020, a day before the event date and other part from 13 March 2020 to 24 
April 2020, a day after the event day. All the sectoral indices including Healthcare index fell 
steeply on the event day 12 March; post that period the test sector has outperformed the other 
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Pre-Event Mean Post-Event Mean T-Statistic 
BSE SENSEX 0.0524 -0.4769 1.0435 
BSE HEALTHCARE 0.0251 0.1814 -0.4020 
BSE AUTO 0.0141 -0.7207 1.4021 
BSE BASIC MATERIALS 0.0133 -0.5994 1.2333 
BSE CONSUMER DISCRETIONARY 0.0577 -0.5756 1.4475 
BSE REALTY 0.1522 -1.1157 2.5784 
BSE IT 0.0190 -0.3689 0.8175 
BSE BANKEX 0.0561 -0.8208 1.4057 
BSE FMCG 0.0147 -0.1412 0.3715 
BSE TECK 0.0287 -0.3441 0.8084 
BSE METAL -0.0483 -0.8571 1.3991 
BSE OIL & GAS -0.0174 -0.4087 0.7749 
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Figure 3: Comparison of daily abnormal returns of BSE Healthcare sector with different sectors 
 
4.1 Event Study 
The last step in the analysis is to apply event study methodology to examine the relationship 
between this pandemic and performance of Indian healthcare and pharmaceutical stocks. Table 
III presents abnormal returns (AR) for the post-event window from day -27 to day 27 (i.e., from 
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are significantly abnormal returns on 26 days, out of which it has given negative returns on 
only 7 days. Returns are statistically significant and negative at 90 per cent confidence interval 
(C.I.) on day -12, -8, -1 and positive at same C.I. on day -22, -18, 1, 21. They are statistically 
significant at 95 per cent C.I.; and negative returns on day 4, and positive returns on day -14, -
5, 3, 13, 18. Abnormal returns are negative and statistically significant at 99 per cent C.I. on 
day 0, 9, 22; and positive at 99 per cent C.I. on day -22, -6, 6, 12, 15, 16, 17, 19, 24, 27. On 
event day 12 March (day 0), abnormal return is negative and significantly high even on 99.9 
per cent C.I. Post-event day returns are positive and significant on most of the days, implying 
an upside in healthcare and pharmaceutical stocks. 
 
Table III – AR of Healthcare Index during post-event period 
 
Day AR t-test  Day AR t-test  
-27 -0.2835 -0.4057  1 1.2837 1.8374 * 
-26 -0.1441 -0.2062  2 0.4678 0.6696  
-25 -0.1451 -0.2077  3 1.3838 1.9808 ** 
-24 -0.0414 -0.0592  4 -1.6675 -2.3869 ** 
-23 0.5820 0.8331  5 -0.7374 -1.0555  
-22 1.8078 2.5877 *** 6 2.0789 2.9757 *** 
-21 -0.0758 -0.1084  7 -0.9745 -1.3949  
-20 0.3436 0.4919  8 0.8936 1.2790  
-19 -0.7192 -1.0294  9 -2.1673 -3.1022 *** 
-18 1.1910 1.7048 * 10 -1.0548 -1.5099  
-17 0.0460 0.0658  11 0.4235 0.6062  
-16 -1.2439 -1.7805 * 12 3.6106 5.1682 *** 
-15 0.2268 0.3246  13 1.3987 2.0021 ** 
-14 1.5412 2.2060 ** 14 0.7615 1.0900  
-13 0.4325 0.6191  15 4.7962 6.8651 *** 
-12 -1.2236 -1.7514 * 16 3.9466 5.6490 *** 
-11 -1.0755 -1.5394  17 4.0913 5.8562 *** 
-10 -0.3956 -0.5662  18 1.4774 2.1148 ** 
-9 0.3995 0.5719  19 2.3003 3.2926 *** 
-8 -1.3311 -1.9053 * 20 0.4644 0.6647  
-7 -0.2495 -0.3571  21 1.1969 1.7132 * 
-6 3.0305 4.3377 *** 22 -2.3956 -3.4290 *** 
-5 1.4285 2.0447 ** 23 -0.0127 -0.0182  
-4 0.3760 0.5383  24 3.0748 4.4011 *** 
-3 0.0081 0.0115  25 -1.1214 -1.6051  
-2 -0.5119 -0.7327  26 -0.3240 -0.4637  
-1 -1.1971 -1.7135 * 27 2.3525 3.3673 *** 
0 -4.0533 -5.8018 ***     
Note: * Significant level 0.1; ** Significant level 0.05; ***Significant level 0.01 Note: Above 
table is based on author’s analysis 
 
 




Table IV – CAR during post-event period 
 
Day CAR t-test  Day CAR t-test  
0 -4.0533 -5.7689 *** 14 1.6474 0.6054  
1 -2.7696 -2.7873 *** 15 6.4436 2.2927 ** 
2 -2.3018 -1.8914 * 16 10.3902 3.5866 *** 
3 -0.9179 -0.6532  17 14.4815 4.8581 *** 
4 -2.5854 -1.6456 * 18 15.9589 5.2109 *** 
5 -3.3229 -1.9307 * 19 18.2593 5.8110 *** 
6 -1.2439 -0.6692  20 18.7237 5.8152 *** 
7 -2.2184 -1.1163  21 19.9205 6.0447 *** 
8 -1.3249 -0.6285  22 17.5249 5.2009 *** 
9 -3.4921 -1.5717  23 17.5122 5.0877 *** 
10 -4.5470 -1.9512 * 24 20.5870 5.8601 *** 
11 -4.1234 -1.6942 * 25 19.4656 5.4333 *** 
12 -0.5128 -0.2024  26 19.1416 5.2430 *** 
13 0.8859 0.3370  27 21.4941 5.7813 *** 
Note: * Significant level 0.1; ** Significant level 0.05; ***Significant level 0.01 Note: Above 
table is based on author’s analysis 
 
 
Table IV represents cumulative abnormal returns (CAR) for the period after event day. Returns 
are statistically significant and negative at 90 per cent C.I on day 2, 4, 5, 10, 11; 99 per cent 
C.I on day 0 and 1. CAR is statistically significant and positive at 95 per cent C.I on day 15 
and 99 per cent C.I on day 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27. CAR becoming positive 
from negative over a period of time and increasing gradually implies that the test sector has 
outperformed the market and provided significantly different results from the market. 
4.2 Discussion 
 
The results arrived at in the above section have been obtained after performing multilevel 
analysis using different tools. This section details what the results imply. 
Beginning from the first level of analysis, the BSE Healthcare sector has given 14 per cent 
return in the last one month whereas the benchmark index SENSEX reduced by 12 per cent 
during the same period. This implies that the demand for the sector specific stocks during the 
pandemic period and the test sector has performed accordingly. Similar results are obtained 
while analysing the impact of COVID-19 on stock return, distributed into two periods. Here 
also BSE Healthcare index has provided positive returns unlike any other sectoral index, all of 
which gave negative returns during post-event period. Both AR and CAR results imply that 
BSE Healthcare index has given positive returns and returns are statistically significant during 
the post-event period. 
 
 





Healthcare sector promises to grow at a rapid pace in the near future due to development in 
lifestyle of people and life expectancy. India is a premier destination to lead the way to become 
the frontrunner in pharmaceutical industry from its current position of third. This paper studied 
how the outbreak of COVID-19 impacted the stock returns of healthcare sector. BSE 
Healthcare index represents the healthcare and pharmaceutical sector as a whole, and their 
closing prices have been taken as the benchmark for further analysis. The results show that 
COVID-19 outbreak significantly affects the stock performance of the sector. There was 
significantly positive CAR continuously from day 16 to day 27. There was significantly 
negative AR on event day, day 0. The result of this paper is consistent with the result of Wang 
et al. (2013) after day 15, but before day 12 stock returns indicate significantly negative 
cumulative abnormal returns. 
Investors believe that the healthcare and pharmaceutical companies will be the beneficiaries of 
this pandemic as they would invest in research and development to prepare for the current 
pandemic and any such unfortunate events in the future. Positive abnormal returns (though not 
all of them are significant) even after 2 weeks of event day (day 0) imply that investors are in 
the sector for a long haul and are continuously pouring money in the healthcare and 
pharmaceutical stocks. This study would be useful for private equity firms and venture 
capitalists who want to invest in uncertain times, where many sectors would underperform due 
to low demand and further growth. Healthcare and pharmaceutical companies would be 
operating in an effective manner to fulfil the demand for their products and services, which 
would in turn increase their operating ability and turnover, making them the most lucrative 
option for investors. 
This type of study considering the Indian stock market is one of a few, but the study is limited 
to companies included in the BSE Healthcare index and does not include any company in the 
same sector outside the index. Also, since there are no separate sectoral indices for healthcare 
and pharmaceutical companies, this study has taken BSE Healthcare index to represent both 
the sectors. 
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